Zymeworks Files 8-K on Operations & Financial Condition

TL;DR

**Zymeworks just filed an 8-K, expect financial updates soon!**

AI Summary

Zymeworks Inc. filed an 8-K on January 4, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is providing an update on its financial status and other significant happenings, though the specific details of these events are not included in this summary. For investors, this means Zymeworks is likely preparing to release or has just released important financial information, which could impact the stock's valuation depending on the nature of the results.

Why It Matters

This filing signals that Zymeworks is updating the market on its financial health and other key developments, which could influence investor sentiment and stock price.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing indicating an upcoming or recent disclosure, not a disclosure of negative events itself.

Analyst Insight

Investors should look for the actual detailed financial results or other event descriptions that this 8-K is foreshadowing, as this filing itself provides no specific financial data or operational changes.

Key Numbers

• 2024-01-04 — Date of Report (The earliest event reported in this 8-K filing.)
• 001-41535 — Commission File Number (Unique identifier for Zymeworks Inc. with the SEC.)
• $0.00001 — par value per share (The par value of Zymeworks Inc.'s Common Stock.)

Key Players & Entities

• Zymeworks Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Zymeworks Inc.
• 001-41535 (dollar_amount) — Commission File Number for Zymeworks Inc.
• 108 Patriot Drive, Suite A (company) — business address of Zymeworks Inc.
• Middletown, Delaware (company) — city and state of Zymeworks Inc.'s business address
• 19709 (dollar_amount) — zip code of Zymeworks Inc.'s business address
• 302-274-8744 (dollar_amount) — telephone number for Zymeworks Inc.
• ZYME (company) — trading symbol for Zymeworks Inc.
• The Nasdaq Stock Market LLC (company) — exchange where Zymeworks Inc.'s common stock is registered

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
• $455 million — marketable securities, of approximately $455 million. The Company also announced that it exp

Filing Documents

• d553940d8k.htm (8-K) — 30KB
• d553940dex99.htm (EX-99) — 38KB
• g553940g0103100705584.jpg (GRAPHIC) — 4KB
• 0001193125-24-001850.txt ( ) — 206KB
• zyme-20240104.xsd (EX-101.SCH) — 3KB
• zyme-20240104_lab.xml (EX-101.LAB) — 18KB
• zyme-20240104_pre.xml (EX-101.PRE) — 11KB
• d553940d8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition. On January 4, 2024, Zymeworks Inc. (the "Company") announced certain information relating to the Company's financial condition as of December 31, 2023, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable securities, of approximately $455 million. The Company also announced that it expects such cash resources to fund the Company's current planned operations into the second half of 2027 (such information, the "Financial Condition Information"). The Financial Condition Information is set forth in a press release issued by the Company on January 4, 2024 under the caption "Updated Financial Guidance". The preliminary and unaudited estimate of cash resources is based on management's initial analysis of operations for the quarter and year ended December 31, 2023, and is subject to further internal review and audit by the Company's external auditors. A copy of this press release is attached hereto as Exhibit 99.1. The press release is incorporated herein by reference, except for the Financial Condition Information, which information is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events. On January 4, 2024, the Company issued a press release announcing a corporate update on its strategic priorities and other matters. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference, except for the Financial Condition Information, which information is furnished as described under Item 2.02 above.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are identified by such words as "believe," "expect," "anticipate" and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company's plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the Company's preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable securities, and the Company's anticipated funding of its current operations and related expected timelines. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date. Furthermore, the Company is in the process of finalizing its financial results for the fourth quarter and fiscal year ended December 31, 2023, and therefore the Company's finalized and audited results and final analysis of those results are not yet available. The preliminary expectations regarding year-end cash, cash equivalents, and marketable securities are the responsibility of management, are subject to management's review and actual results could differ from management's expectations. The actual results are also subject to audit by the Company's independent registered public accounting firm and no assurance is given by the Company's independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December 31, 2023, based on the foregoing estimates.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 4, 2024. 104 Cover Page Interactive Data File (embedded as Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: January 4, 2024 By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair and Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR